- Home
- SITE vs RLAY Comparison
SITE vs RLAY Comparison
Compare SITE & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITE | RLAY |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.1B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SITE | RLAY |
|---|---|---|
| Price | $100.58 | $19.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $160.38 | $19.50 |
| AVG Volume (30 Days) | 637.5K | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.35 | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,704,800,000.00 | $15,355,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $4.08 | $324.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.62 | ★ 53.44 |
| 52 Week Low | $90.07 | $3.89 |
| 52 Week High | $168.56 | $21.27 |
Technical Indicators
Market Signals| Indicator | SITE | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 43.70 |
| Support Level | $93.10 | $18.02 |
| Resistance Level | $99.31 | $20.82 |
| Average True Range (ATR) | 2.55 | 0.87 |
| MACD | 0.61 | -0.24 |
| Stochastic Oscillator | 72.25 | 21.00 |
Price Performance
Historical ComparisonAbout SITE SiteOne Landscape Supply Inc.
SiteOne Landscape Supply Inc is a national full product line wholesale distributor of landscape supplies in the United States and has an established presence in Canada. Its customers are mainly residential and commercial landscape professionals who specialized in the design, installation, and maintenance of lawns, gardens, golf courses, and other outdoor spaces.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.